Security Snapshot

BIODELIVERY SCIENCES INTL IN - COM (BDSI) Institutional Ownership

CUSIP: 09060J106

13F Institutional Holders and Ownership History from Q1 2014 to Q2 2022

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • BDSI - BIODELIVERY SCIENCES INTL IN - COM is tracked under CUSIP 09060J106.
  • Latest finished 13F holder period is not available.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 3 to 0 between Q1 2022 and Q2 2022.
  • SEC-reported value moved from $27,000 to $0.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

09060J106

Latest holder period

n/a

13F holders

13D/G owners

0

CIK / CUSIP context first

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
34
Latest
n/a
Rows shown
1-25 of 34
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2022 Q2 0 $0 -$26,000 0
2022 Q1 8,750 $27,000 -$181,040,661 $3.07 3
2021 Q4 58,536,918 $181,490,374 -$10,079,655 $3.10 148
2021 Q3 61,187,116 $221,508,992 +$6,762,180 $3.61 141
2021 Q2 59,304,508 $212,320,171 -$18,936,436 $3.58 136
2021 Q1 64,220,640 $251,057,006 -$16,470,224 $3.91 142
2020 Q4 67,581,854 $283,860,010 -$3,504,377 $4.20 138
2020 Q3 67,576,088 $252,069,856 -$14,049,109 $3.73 140
2020 Q2 70,865,521 $308,967,448 +$9,841,907 $4.36 155
2020 Q1 69,267,360 $262,516,605 +$7,100,389 $3.79 150
2019 Q4 69,386,555 $438,522,799 +$62,705,220 $6.32 155
2019 Q3 60,841,273 $256,209,479 +$3,687,790 $4.21 117
2019 Q2 60,858,735 $282,905,171 +$45,899,619 $4.65 109
2019 Q1 50,779,672 $269,130,000 +$61,434,611 $5.30 101
2018 Q4 40,102,105 $151,955,000 +$15,803,782 $3.70 81
2018 Q3 37,253,674 $104,189,000 +$28,275,326 $2.80 75
2018 Q2 27,070,375 $79,860,000 -$35,554 $2.95 63
2018 Q1 27,292,787 $61,422,000 +$768,865 $2.25 62
2017 Q4 26,783,113 $79,003,000 +$6,357,683 $2.95 66
2017 Q3 24,630,338 $72,656,000 +$5,072,420 $2.95 59
2017 Q2 22,972,955 $64,321,000 +$3,711,751 $2.80 61
2017 Q1 22,143,627 $42,116,000 +$322,927 $1.90 60
2016 Q4 23,345,045 $40,816,000 -$9,287,345 $1.75 74
2016 Q3 27,726,103 $74,179,989 -$10,552,846 $2.70 79
2016 Q2 32,055,115 $75,645,634 -$18,582,880 $2.36 84
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .